In ovarian cancer, the most frequent actionable targets identified were ER (41%), PD1 (16.7%), and EFGR (11.5%), whereas in endometrial cancer, ER (58.7%), PTEN (58.7%), and CTNNB1 (19.6%) were more common. This evidence concerns the gene PTEN and ovarian carcinoma.